Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Cancer Reports (Hoboken, N.J.)
|
November 7, 2025
ICIs Exceptional Long Response in TNBC: Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the Literature
Simone Rota, Carolina Sciortino, Silvia Damian, et al.
Clinical Breast Cancer
|
January 13, 2019
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles
Claudio Vernieri, Michele Prisciandaro, Monica Milano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 4, 2012
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Axel Le Cesne, Sara Cresta, Robert G Maki, et al.
Scientific Reports
|
February 9, 2024
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade
Licia Rivoltini, Chiara Camisaschi, Giovanni Fucà, et al.
Cancers
|
February 17, 2019
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
Maria Silvia Cona, Mara Lecchi, Sara Cresta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Antonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
Cancer Research
|
July 13, 2016
miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
Elvira D'Ippolito, Ilaria Plantamura, Lucia Bongiovanni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2006
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
Michael C Heinrich, Grant A McArthur, George D Demetri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2021
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Komal Jhaveri, Dejan Juric, Yoon-Sim Yap, et al.
Tumori
|
April 27, 2024
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials
Luca Agnelli, Andrea Villa, Fouziah Butt, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Cancer Reports (Hoboken, N.J.)
|
November 7, 2025
ICIs Exceptional Long Response in TNBC: Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the Literature
Simone Rota, Carolina Sciortino, Silvia Damian, et al.
Clinical Breast Cancer
|
January 13, 2019
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles
Claudio Vernieri, Michele Prisciandaro, Monica Milano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 4, 2012
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Axel Le Cesne, Sara Cresta, Robert G Maki, et al.
Scientific Reports
|
February 9, 2024
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade
Licia Rivoltini, Chiara Camisaschi, Giovanni Fucà, et al.
Cancers
|
February 17, 2019
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
Maria Silvia Cona, Mara Lecchi, Sara Cresta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Antonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
Cancer Research
|
July 13, 2016
miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
Elvira D'Ippolito, Ilaria Plantamura, Lucia Bongiovanni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2006
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
Michael C Heinrich, Grant A McArthur, George D Demetri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2021
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Komal Jhaveri, Dejan Juric, Yoon-Sim Yap, et al.
Tumori
|
April 27, 2024
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials
Luca Agnelli, Andrea Villa, Fouziah Butt, et al.
Page
of 3